Harvest Technologies Corp.
This article was originally published in Start Up
Executive Summary
Harvest is building upon the autotransfusion concept to create devices which not only have the capacity to collect a patient's blood just prior to and during surgery, but which can also convert collected blood into autologous blood products that promote post-surgical wound healing, bone growth and hemostasis.
You may also be interested in...
Harvest Steps into Stem Cells
Harvest Technologies, a 14-year-old player in the blood and marrow supply arena, is moving aggressively into the business of selling stem cells therapies for cardiovascular disease.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.